US OKs first oral GLP‑1 obesity pill

FDA clears first daily oral GLP‑1 for obesity care

The US Food and Drug Administration has approved a once‑daily oral GLP‑1 medicine from Novo Nordisk for long‑term weight management, marking the first time a GLP‑1–based obesity treatment is available in pill form. The therapy is indicated to help adults with obesity or overweight reduce excess body weight and maintain that weight loss when used alongside a reduced‑calorie diet and increased physical activity.

Novo Nordisk said it expects to launch the pill in the United States in early January 2026. The company presented the approval as a milestone because GLP‑1 therapies with similar efficacy had previously required injections, which some patients have been reluctant to use. The new oral option is designed to give those patients an alternative starting point or a way to continue medical obesity care without needles.

Mike Doustdar, Novo Nordisk’s president and CEO, said in a statement that the pill offers weight‑loss results comparable to injectable GLP‑1 therapy and no current oral GLP‑1 treatment matches its effect. He described the approval as providing a convenient pill option for people living with overweight or obesity who need medical support for weight management.

Clinical data show injectable‑like weight loss

Pivotal data from the global OASIS 4 trial underpinned the FDA decision. According to Novo Nordisk, participants taking the once‑daily oral GLP‑1 for about a year lost an average of 16.6% of their starting body weight. One in three patients achieved weight loss of more than 20%, a threshold the company linked to meaningful improvements in daily functioning and quality of life for people with obesity.

The trial results suggest the oral formulation can deliver weight‑loss outcomes comparable to Novo Nordisk’s once‑weekly injectable GLP‑1 product that is already marketed for weight management. The company highlighted that the new pill is a prescription medicine to be used under medical supervision, with dosing embedded in a broader obesity treatment plan that also emphasizes diet and physical activity.

Experts cited in the company’s materials stress that obesity is a complex, chronic disease rather than a simple failure of willpower. In many patients, hormonal systems that regulate hunger and fullness are disrupted and the body defends a higher weight. GLP‑1 drugs mimic a natural hormone acting on appetite centers in the brain, helping patients feel fuller longer, reduce food intake and achieve gradual, more sustainable weight loss.

Cardiovascular risk reduction built into indication

Beyond weight management, the oral GLP‑1 pill is also approved in the United States to reduce the risk of major adverse cardiovascular events in certain patient groups. Clinical data showed approximately a 20% reduction in cardiovascular risk among patients with heart disease who also had obesity or overweight, according to Novo Nordisk.

The indication covers events such as cardiovascular death, non‑fatal myocardial infarction and non‑fatal stroke. The company framed this dual effect as evidence that medical obesity care extends beyond appearance, offering meaningful protection for heart health and the potential to extend lifespan for eligible patients.

Novo Nordisk said previous studies of GLP‑1–based weight management have shown improvements in risk factors related to heart health and metabolic function in many patients, including those with conditions such as type 2 diabetes, high blood pressure and abnormal blood lipids, which commonly accompany obesity.

Global implications and Indonesia focus

Novo Nordisk positioned the US approval as a signal of where obesity treatment is heading globally. The company linked the development to the situation in Indonesia, where obesity and central obesity are rising and associated with chronic diseases including diabetes, hypertension, heart disease and stroke.

Citing the 2023 Indonesia Health Survey, Novo Nordisk noted that 23.4% of Indonesian adults live with obesity and central obesity affects 36.8% of people aged 15 and above. A 2016 study from Bogor Agricultural University estimated obesity‑related economic losses in Indonesia at tens of billions of rupiah annually when accounting for healthcare spending and productivity losses.

Sreerekha Sreenivasan, general manager of Novo Nordisk Indonesia, said the GLP‑1 innovation is part of a long‑term mission to transform obesity care in the country. She emphasized that many Indonesians find lifestyle changes alone insufficient and deserve access to comprehensive medical support. In Indonesia, a once‑weekly injectable GLP‑1 therapy from Novo Nordisk is already available for patients as part of medical management of obesity.

Education, access and evolving view of obesity

Novo Nordisk said its current focus in Indonesia is on education, building healthcare capacity and expanding access to existing obesity treatments. The company is working with healthcare professionals and other stakeholders to reinforce the view of obesity as a serious chronic disease requiring medical attention rather than a matter of appearance.

To support this, the company promotes NovoCare.id, an educational website with information on obesity, its health risks and evidence‑based weight‑management approaches, including the role of GLP‑1 therapies. It encourages people who struggle to lose weight, have abdominal obesity or have related conditions such as diabetes or hypertension to seek a medical assessment and tailored treatment plan.

Although the new oral GLP‑1 pill will initially be launched in the United States, Novo Nordisk said its development illustrates how scientific advances are equipping the medical community to treat obesity more effectively. The company argued that innovations like once‑daily oral GLP‑1 medicines can help move public discussion toward long‑term health and survival outcomes for people living with obesity.